4
|
Loyer X, Paradis V, Hénique C, Vion AC, Colnot N, Guerin CL, Devue C, On S, Scetbun J, Romain M, Paul JL, Rothenberg ME, Marcellin P, Durand F, Bedossa P, Prip-Buus C, Baugé E, Staels B, Boulanger CM, Tedgui A, Rautou PE. Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression. Gut 2016; 65:1882-1894. [PMID: 26338827 PMCID: PMC5099209 DOI: 10.1136/gutjnl-2014-308883] [Citation(s) in RCA: 112] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/24/2014] [Revised: 08/09/2015] [Accepted: 08/13/2015] [Indexed: 12/13/2022]
Abstract
OBJECTIVE Previous studies suggested that microRNA-21 may be upregulated in the liver in non-alcoholic steatohepatitis (NASH), but its role in the development of this disease remains unknown. This study aimed to determine the role of microRNA-21 in NASH. DESIGN We inhibited or suppressed microRNA-21 in different mouse models of NASH: (a) low-density lipoprotein receptor-deficient (Ldlr-/-) mice fed a high-fat diet and treated with antagomir-21 or antagomir control; (b) microRNA-21-deficient and wild-type mice fed a methionine-choline-deficient (MCD) diet; (c) peroxisome proliferation-activator receptor α (PPARα)-deficient mice fed an MCD diet and treated with antagomir-21 or antagomir control. We assessed features of NASH and determined liver microRNA-21 levels and cell localisation. MicroRNA-21 levels were also quantified in the liver of patients with NASH, bland steatosis or normal liver and localisation was determined. RESULTS Inhibiting or suppressing liver microRNA-21 expression reduced liver cell injury, inflammation and fibrogenesis without affecting liver lipid accumulation in Ldlr-/- fed a high-fat diet and in wild-type mice fed an MCD diet. Liver microRNA-21 was overexpressed, primarily in biliary and inflammatory cells, in mouse models as well as in patients with NASH, but not in patients with bland steatosis. PPARα, a known microRNA-21 target, implicated in NASH, was decreased in the liver of mice with NASH and restored following microRNA-21 inhibition or suppression. The effect of antagomir-21 was lost in PPARα-deficient mice. CONCLUSIONS MicroRNA-21 inhibition or suppression decreases liver injury, inflammation and fibrosis, by restoring PPARα expression. Antagomir-21 might be a future therapeutic strategy for NASH.
Collapse
Affiliation(s)
- Xavier Loyer
- INSERM, U970, Paris Cardiovascular Research Center—PARCC, Paris, France,Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Valérie Paradis
- Service d'Anatomie Pathologique, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Clichy, France,INSERM, U773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, Clichy, France,Université Denis Diderot-Paris 7, Sorbonne Paris Cité, Paris, France
| | - Carole Hénique
- INSERM, U970, Paris Cardiovascular Research Center—PARCC, Paris, France,Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Anne-Clémence Vion
- INSERM, U970, Paris Cardiovascular Research Center—PARCC, Paris, France,Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Nathalie Colnot
- Service d'Anatomie Pathologique, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Clichy, France
| | - Coralie L Guerin
- INSERM, U970, Paris Cardiovascular Research Center—PARCC, Paris, France,Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Cécile Devue
- INSERM, U970, Paris Cardiovascular Research Center—PARCC, Paris, France,Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Sissi On
- INSERM, U970, Paris Cardiovascular Research Center—PARCC, Paris, France,Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Jérémy Scetbun
- INSERM, U970, Paris Cardiovascular Research Center—PARCC, Paris, France,Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Mélissa Romain
- INSERM, U970, Paris Cardiovascular Research Center—PARCC, Paris, France,Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Jean-Louis Paul
- Service de Biochimie, Hôpital Européen Georges Pompidou, AP-HP (Assistance Publique-Hôpitaux de Paris), Paris, France
| | - Marc E Rothenberg
- Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
| | - Patrick Marcellin
- INSERM, U773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, Clichy, France,Université Denis Diderot-Paris 7, Sorbonne Paris Cité, Paris, France,Service d'Hépatologie, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Clichy, France
| | - François Durand
- INSERM, U773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, Clichy, France,Université Denis Diderot-Paris 7, Sorbonne Paris Cité, Paris, France,Service d'Hépatologie, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Clichy, France
| | - Pierre Bedossa
- Service d'Anatomie Pathologique, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Clichy, France,INSERM, U773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, Clichy, France,Université Denis Diderot-Paris 7, Sorbonne Paris Cité, Paris, France
| | - Carina Prip-Buus
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France,INSERM, U1016, Institut Cochin, Paris, France,CNRS, UMR8104, Paris, France
| | - Eric Baugé
- Univ. Lille, Inserm, Institut Pasteur de Lille, U1011—EGID, Lille, France
| | - Bart Staels
- Univ. Lille, Inserm, Institut Pasteur de Lille, U1011—EGID, Lille, France
| | - Chantal M Boulanger
- INSERM, U970, Paris Cardiovascular Research Center—PARCC, Paris, France,Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Alain Tedgui
- INSERM, U970, Paris Cardiovascular Research Center—PARCC, Paris, France,Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Pierre-Emmanuel Rautou
- INSERM, U970, Paris Cardiovascular Research Center—PARCC, Paris, France,Université Paris Descartes, Sorbonne Paris Cité, Paris, France,Université Denis Diderot-Paris 7, Sorbonne Paris Cité, Paris, France,Service d'Hépatologie, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Clichy, France
| |
Collapse
|